


Listing of Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of the formula



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)- and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, provided that when R is OH and Y is =N- the ring A is not unsubstituted, and pharmaceutically acceptable salts thereof.

2. (Currently Amended) A compound according to claim 1 of formula 1A




wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is hydrogen, halogen or nitro, provided that when R is OH and Y is =N- Z is not H, and pharmaceutically acceptable salts thereof.

3. (Previously Presented) A compound according to claim 2, wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is halogen.
4. (Currently Amended) The A compounds selected from: 1-oxy-quinoline-4-carboxylic acid [(2R,4S)-1-(3,5-bis-trifluoromethyl-benzoyl)-2-(4-chloro-benzyl)piperidin-4-yl]-amide or a pharmaceutically acceptable salt thereof, or 2-hydroxy-quinoline-4-carboxylic acid [(2R,4S)-1-(3,5-bis-trifluoromethyl-benzoyl)-2-(4-chloro-benzyl)-piperidin-4-yl]-amide (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-quinoline-N-oxide-4-carboxamide or a pharmaceutically acceptable salt thereof, or (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-3-hydroxy-quinoline-4-carboxamide or a pharmaceutically acceptable salt thereof.
4. (Previously Presented) A method of treating a condition characterized by substance-P induction, in an animal in need thereof comprising: administering an amount of substance-P antagonist effective to inhibit the induction of substance-P, wherein the substance-P antagonist is a compound according to Claim 1.
5. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1.
6. (cancelled)

7. (Previously Presented) A process for the preparation of a compound of Formula I, comprising:

oxidising a compound of formula II;



optionally separating a mixture of isomers obtainable by the process and isolating the desired isomer of the resulting oxidized compound.